P. Patel

发表

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

Nicole Lewis, W. Spreen, Y. Lou, 2019, Antiviral therapy.

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

S. Piscitelli, Y. Lou, T. Wajima, 2011, Antimicrobial Agents and Chemotherapy.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

S. Swindells, C. Orrell, Kimberly Smith, 2020, The Lancet.

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

S. Swindells, S. Oka, C. Orkin, 2020, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

S. Piscitelli, T. Wajima, P. Patel, 2013, Clinical pharmacology in drug development.

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

A. LaMarca, D. Mcclernon, E. Dejesus, 2009, AIDS research and therapy.

A. LaMarca, D. Mcclernon, E. Dejesus, 2009 .

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis

S. Riddler, E. Fuchs, C. Hendrix, 2021, British journal of clinical pharmacology.

the Pharmacokinetics of Dolutegravir Ritonavir-Boosted Protease Inhibitors on Effects of Etravirine Alone and with

S. Piscitelli, Y. Lou, T. Wajima, 2011 .

Intrapulmonary Pharmacokinetics of GSK2251052 in Healthy Volunteers

K. Rodvold, G. Bowers, J. Tomayko, 2013, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

S. Swindells, S. Letendre, H. Crauwels, 2019, The Journal of antimicrobial chemotherapy.

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls

W. Spreen, A. Tenorio, Y. Lou, 2019, Clinical pharmacology in drug development.

885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials

J. Polli, V. Vannappagari, H. Crauwels, 2021, HIV medicine.

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.

H. Stellbrink, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

Lamivudine for the treatment of HIV

P. Patel, Princy N. Kumar, 2010, Expert opinion on drug metabolism & toxicology.

Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials

C. Harrington, P. Patel, P. Benn, 2022, Journal of acquired immune deficiency syndromes.

Effect of a High‐Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir

W. Spreen, A. Tenorio, Y. Lou, 2018, Clinical pharmacology in drug development.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants

Caifeng Fu, W. Spreen, A. Tenorio, 2019, Clinical pharmacology in drug development.

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

W. Spreen, A. Tenorio, Y. Lou, 2017, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

S. Piscitelli, Apurva Patel, Y. Lou, 2011, The Journal of antimicrobial chemotherapy.

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

P. Cahn, S. Swindells, J. Mrus, 2020, The New England journal of medicine.

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

S. Oka, S. Walmsley, C. Orkin, 2020, The New England journal of medicine.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

D. Kuritzkes, J. Schapiro, J. Polli, 2021, AIDS.

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir

K. King, A. Hughes, W. Spreen, 2020, The Journal of antimicrobial chemotherapy.

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

R. Grant, I. Frank, M. Murray, 2018, HIV clinical trials.

Drug Interactions in HIV: Protease and Integrase Inhibitors

S. Louie, P. Patel, 2018 .

Relative Bioavailability of a Paediatric Granule Formulation of the HIV Integrase Inhibitor Dolutegravir in Healthy Adult Subjects

S. Piscitelli, T. Wajima, P. Patel, 2014, Antiviral therapy.

Multiparametric magnetic resonance imaging to characterize cabotegravir long‐acting formulation depot kinetics in healthy adult volunteers

M. Solaiyappan, K. Macura, M. Jacobs, 2021, British journal of clinical pharmacology.

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

M. Marzinke, R. Landovitz, W. Spreen, 2022, British journal of clinical pharmacology.

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

S. Oka, C. Orkin, Kimberly Smith, 2021, The lancet. HIV.

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

Sterling Wu, C. Harrington, D. Margolis, 2020 .

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

S. Piscitelli, Y. Lou, P. Patel, 2011, Journal of clinical pharmacology.

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects

W. Spreen, Y. Lou, S. Ford, 2016, Clinical pharmacology in drug development.

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.

D. Kuritzkes, J. Schapiro, J. Polli, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority t

S. Oka, S. Walmsley, G. di Perri, 2023, The lancet. HIV.

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

S. Piscitelli, Y. Lou, P. Patel, 2011, Journal of clinical pharmacology.

Lamivudine for the treatment of HIV

P. Patel, Princy N. Kumar, 2010, Expert Opinion on Drug Metabolism & Toxicology.

Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.

H. Crauwels, P. Patel, E. Birmingham, 2023, The Journal of infectious diseases.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.

Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP

S. Delany-Moretlwe, M. Marzinke, W. Spreen, 2024, Antimicrobial agents and chemotherapy.